Atlanta – September 15, 2026 -- Medication nonadherence costs the U.S. healthcare system as much as $300 billion annually, a gap Response Media is targeting with the launch of a new health and life sciences practice called RE:HEALTH.
Response Media debuts AdherenceIQ to predict patient drop-off before it happens
The agency introduced AdherenceIQ, a proprietary AI-powered behavioral intelligence platform designed to predict which patients will discontinue therapy and why. The tool combines behavioral science, privacy-compliant AI and advanced analytics to identify emotional and functional barriers to treatment, including concerns about side effects, necessity, distrust and stigma.
Platform targets chronic and rare disease therapies where persistence drives commercial outcomes
For chronic and rare disease treatments, where adherence directly affects patient outcomes and TRx growth, AdherenceIQ shifts the model from measuring attrition after the fact to flagging at-risk patients while intervention is still possible. The platform recommends engagement strategies based on the specific barriers it detects for each patient segment.
Executives argue pharma has marketed medicine as functional, not emotional
"Medicine is an emotional decision but the industry has marketed it as a functional one,